SAN DIEGO & BERLIN & DURHAM, N.C.–(BUSINESS WIRE)–Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, today announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company. Vividion is a wholly owned and independently operating subsidiary of Bayer AG. The

NATICK, Mass.–(BUSINESS WIRE)–Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivotal trial evaluating the safety and efficacy of the Allurion Balloon. The AUDACITY trial is an open-label, multicenter, randomized, controlled study and is the first FDA pivotal trial on an intragastric balloon for weight loss to report primary outcomes beyond 9 months. 550 subjects were random

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinical trial collaboration and supply agreement with Amgen (NASDAQ:AMGN) to evaluate etakafusp alfa (formerly known as AB248), Asher Bio’s investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, in combination with IMDELLTRA® (tarlatamab), Amgen’s DLL3-targeting Bispecific T-cell Engage

MIAMI–(BUSINESS WIRE)–Ontrak, Inc (NASDAQ: OTRK), (“Ontrak” or the “Company”), an AI-powered and telehealth-enabled behavioral healthcare company, announced it has signed an agreement to provide its behavioral health solutions to Intermountain Health’s Medicare Advantage members in Nevada. Intermountain Health is a prominent healthcare system operating 400 clinics and 34 hospitals in the western United States. Intermountain Health is known for its high quality, affordable and personalized car

BOSTON–(BUSINESS WIRE)–AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, announced today it has entered into a Collaborative Research Agreement with the University of Missouri-Columbia to work with Dr. Carolyn Anderson, Simón-Ellebracht Professor in Medicinal Chemistry and Professor of Radiology, and her team to jointly pursue specific research projects to advance the use of de novo designed miniproteins for targe

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced three abstracts were accepted to be presented at several upcoming industry conferences including ASCO Gastrointestinal Cancers Symposium (ASCO GI) 2025, Society of Interventional Oncology (SIO) 2025 and Society of Surgical Oncology (SSO) 20

BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development a

FARMINGTON, Conn.–(BUSINESS WIRE)–Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon” or the “Company”), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced it has provided a $35 million venture loan facility to Onkos Surgical (“Onkos”), of which $30 million h

TORONTO–(BUSINESS WIRE)–Breast Cancer Canada is committed to its mission to advance breast cancer research, advocacy, and equitable access in 2025.

EMERYVILLE, Calif.–(BUSINESS WIRE)– #biotech–Fauna Bio announces first candidate nomination of Faun1083 for the treatment of heart failure.